Lauxera Capital Partners, with operational bases in Paris and San Francisco, has successfully concluded fundraising for its second Healthtech growth fund, known as Lauxera Growth II. The firm exceeded its target of €400 million, achieving this milestone in an impressively short timeframe. This fund is aligned with Lauxera’s mission to transform Europe’s healthtech innovators into globally recognized leaders by providing a hands-on operational strategy that sets it apart from conventional investors.
Vision and Leadership
Established in 2020 by a trio of professionals including Samuel Levy, a physician turned entrepreneur, Pierre Moustial, an experienced pharmaceutical executive with a background in CEO roles, and Alex Slack, a specialist in healthcare investments, Lauxera brings a diverse mix of medical insight, industry expertise, and investment acumen. According to Pierre Moustial, who serves as Co-Founding Partner, the swift completion of this fundraising effort, particularly amid challenging market conditions, reflects the strong confidence investors have in the firm’s vision. He emphasized the importance of their transatlantic presence in facilitating the emergence and scaling of effective healthtech solutions.
Strategic Investments
Already, Lauxera Growth II has engaged in significant investments, including a €50 million stake in Acandis, a Germany-based company that specializes in developing advanced neurovascular devices for the treatment of strokes and aneurysms. Acandis has established a strong manufacturing presence across more than 60 countries, enhancing its global reach. Another notable investment has been made in Antaros Medical, located in Sweden, which utilizes AI-driven imaging technologies to streamline clinical trials, particularly in fields like obesity and immunology.
Operational Support Model
Distinct from many European funds that adopt an earlier or less involved investment strategy, Lauxera emphasizes operational support for its portfolio companies. The firm assists in maneuvering through the intricate U.S. regulatory landscape, scaling commercial operations, and facilitating international expansion. This operational approach proved effective with Lauxera Growth I’s portfolio company OrganOx, which was acquired by Terumo, a Japan-based corporation, for $1.5 billion in August 2025.
Future Outlook
With a meticulous review process that evaluates over 1,000 opportunities annually, Lauxera has built a reputation that resonates with both investors and entrepreneurs, particularly those looking to transcend Europe’s fragmented healthcare markets. The firm is actively seeking new investors for its latest fund and intends to announce a third major investment in the near future. Lauxera is particularly focused on sectors poised for significant innovation, including AI-enhanced diagnostics, intelligent medical devices, and platforms aimed at improving healthcare delivery. This strategic direction positions Lauxera to play a pivotal role in the evolution of healthtech on a global scale.
Related
